Antiphospholipid Antibodies

Subscribe to Selected New Research on Antiphospholipid Antibodies

2624 relevant articles (25 outcomes, 201 trials/studies) found for this Bio-Agent

Description: Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.

Also Known As:

Antibodies, Antiphospholipid; Antiphospholipid Antibody; Antibody, Antiphospholipid

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Asherson, Ronald A: 9 articles (04/2008 - 02/2003)
2.	Cervera, Ricard: 7 articles (10/2008 - 01/2004)
3.	Khamashta, M A: 6 articles (10/2008 - 09/2000)
4.	Pierangeli, Silvia S: 6 articles (04/2008 - 02/2002)
5.	von Landenberg, Philipp: 6 articles (03/2008 - 01/2003)
6.	Shoenfeld, Y: 6 articles (01/2004 - 07/2000)
7.	Galli, Monica: 5 articles (06/2008 - 01/2003)
8.	Ahn, Yeon S: 5 articles (01/2007 - 02/2005)
9.	Bidot, Carlos J: 5 articles (01/2007 - 02/2005)
10.	Horstman, Lawrence L: 5 articles (01/2007 - 02/2005)

Related Diseases

1.	Thrombosis (Thrombus) 03/01/2006 - "EVIDENCE ACQUISITION: Search of MEDLINE (1966 to November 2005) and Cochrane Library electronic databases (2005) and reference lists for randomized trials, meta-analyses of randomized trials, and prospective cohort studies of the treatment of thrombosis risk in patients with antiphospholipid antibodies or APS. " 03/01/2003 - "The aim of this study was to evaluate the prevalence of anti-CD36 in patients with antiphospholipid antibodies (aPL) and its relationship with thrombosis. " 01/01/2002 - "The aim of the study was to determine whether the combined presence of two types of antiphospholipid antibodies can be associated with a high-risk subset of thrombosis-prone patients. " 01/01/2001 - "CONCLUSION: Antiphospholipid antibodies are positive in a high proportion of these patients but thrombosis were not found during the study duration. " 02/01/1998 - "OBJECTIVE: The purpose of this study was to determine the patterns of non-CNS thromboses in patients with a hypercoagulable state associated with antiphospholipid antibodies (APA). " Order ALL the reference details at left...
2.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 04/01/2007 - "OBJECTIVE: To analyze the association of antiphospholipid antibodies (aPL) with the development of clinical thrombotic manifestations and to characterize the efficacy of anti-thrombotic therapies used.METHODS: 272 systemic lupus erythematosus (SLE) patients participated in the study. " 10/01/2009 - "The objective is to study the neuropsychiatric (NP) manifestations in pediatric onset systemic lupus erythematosus (SLE) at a tertiary care hospital of northwestern India applying American College of Rheumatology (ACR) case definitions in the context of occurrence of antiphospholipid antibodies (APLA). " 07/01/2000 - "BACKGROUND: The aim of this study was to evaluate the incidence of morphologic and functional cardiac abnormalities in patients with systemic lupus erythematosus and correlate the data with antiphospholipid antibody (aPL) levels. " 01/01/1999 - "In this study we have examined whether genetic variation in the APOH gene affects variation in risk for systemic lupus erythematosus (SLE), occurrence of antiphospholipid antibodies (APA), anti-apoH, and plasma apoH concentrations. " 11/15/1997 - "A number of studies report the incidence of antiphospholipid antibodies in different patient populations: normal obstetrical patients (5.3% of 7278 women), women with recurrent pregnancy loss (20% of 2226 women), women with systemic lupus erythematosus (37% of 1579 women) and, more recently, women undergoing in vitro fertilization (24% of 3343 women). " Order ALL the reference details at left...
3.	Stroke (Strokes) 01/01/1993 - "This case provides further evidence that effective treatment for stroke associated with antiphospholipid antibodies is still wanting." 11/01/2008 - "In our study, stroke patients with antiphospholipid antibodies (APL) were significantly younger and were more likely to be women than stroke patients without APL. " 10/01/2005 - "No treatment trials have been conducted in young adults with antiphospholipid antibodies and stroke. " 10/01/2005 - "Only one of these studies evaluated for risk of recurrent stroke in young adults with antiphospholipid antibodies and found it to be increased. " 10/01/2005 - "RESULTS: Antiphospholipid antibodies are an independent risk factor for stroke in young adults in five of six studies. " Order ALL the reference details at left...
4.	Fetal Death 06/15/2004 - "OBJECTIVE: To evaluate the efficacy of a uniform management protocol in antiphospholipid-antibody-positive obstetric patients with at least one second- or third-trimester intra-uterine fetal death. " 11/01/1991 - "Antiphospholipid antibody measurements obtained at 15 weeks' gestation or later in the general pregnancy population are not helpful in identifying pregnancies at risk for fetal death." 06/15/2004 - "STUDY DESIGN: A prospective study of 33 successive pregnancies in antiphospholipid-antibody-positive patients, diagnosed after an intra-uterine fetal death. " 09/01/1999 - "Our data do not support routine testing for anti-beta(2)-glycoprotein I in addition to testing for antiphospholipid antibodies in women with recurrent pregnancy loss and unexplained fetal death." 07/01/1998 - "The presence of antiphospholipid antibody largely, but not invariably, predicts fetal death. " Order ALL the reference details at left...
5.	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 11/01/2008 - "OBJECTIVES: The purpose of this study was to obtain data on the association of antiphospholipid antibodies with clinical manifestations in childhood and to enable future studies to determine the impact of treatment and long-term outcome of pediatric antiphospholipid syndrome. " 01/01/2008 - "A total cohort of 1000 patients with antiphospholipid syndrome (APS), derived from 13 countries (Belgium, Bulgaria, Denmark, France, Germany, Greece, Hungary, Israel, Italy, the Netherlands, Portugal, Spain and United Kingdom), has been followed since then by a European consortium that was created as part of the network promoted by the "European Forum on Antiphospholipid Antibodies", a study group devoted to the development of multicentre projects with large populations of APS patients. " 11/01/2007 - "Over the past several years, studies have described the management of patients with key clinical manifestations of antiphospholipid antibodies, including patients with antiphospholipid antibody syndrome. " 09/01/2007 - "RECENT FINDINGS: Limitations in the laboratory testing for antiphospholipid antibodies and changes in the diagnostic criteria for antiphospholipid antibody syndrome are important to recognize as they will affect the type of patients enrolled in the clinical trials evaluating antiphospholipid antibody syndrome therapies. " 02/01/2007 - "OBJECTIVE: Studies that use a murine model of antiphospholipid syndrome have demonstrated a critical role for complement activation that leads to fetal and placental injury in the presence of antiphospholipid antibodies (APAs). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	Anticardiolipin Antibodies
3.	Warfarin (Coumadin)
4.	Lupus Coagulation Inhibitor (Lupus Anticoagulant)
5.	Immunoglobulin G (IgG)
6.	Immunoglobulin M (IgM)
7.	Cardiolipins (Cardiolipin)
8.	Creatinine
9.	Prednisone (Sone)
10.	Phospholipids

Related Therapies and Procedures

1.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
2.	Renal Dialysis (Hemodialysis)
3.	Transplantation (Transplant Recipients)
4.	Plasmapheresis
5.	Immunotherapy

Best Treatments:
Research Summary Report
on Thrombosis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1343 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>